Linked Life Data

16998465

Source:http://linkedlifedata.com/resource/pubmed/id/16998465

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-11-22
pubmed:abstractText
CD4+CD56+ hematodermic neoplasms are rare, aggressive hematopoietic malignancies usually presenting with cutaneous masses followed by a leukemic phase. The blastic morphology, CD56 expression and lack of definitive myeloid or T-cell markers initially resulted in assignment of this tumor to the NK-cell lineage. Accumulating evidence now suggests that these neoplasms represent malignant counterparts to the plasmacytoid dendritic cell. BDCA-2 is a cell surface protein whose expression is restricted to human plasmacytoid dendritic cells, in a differentiation stage-specific manner. In the current study, we assessed expression of BDCA-2 in CD4+CD56+ hematodermic neoplasms using a new antibody reagent we developed for use in fixed tissue sections. In 10 of 19 cases of CD4+CD56+ hematodermic neoplasm, BDCA-2 immunoreactivity was detected, whereas no expression was observed in NK-lineage tumors (0 of six). Interestingly, expression of terminal deoxynucleotidyl transferase, a marker of immaturity/blast stage, was significantly and negatively correlated with BDCA-2 in CD4+CD56+ hematodermic neoplasms whereas a positive correlation was observed between BDCA-2 and CD7. These findings demonstrate that BDCA-2 is expressed predominantly in the CD7+ subset of hematodermic neoplasms, and similar to non-neoplastic plasmacytoid dendritic cells, expression indicates a relatively more mature differentiation state. Clinical follow-up data confirm the aggressiveness of these tumors and suggests that BDCA-2 immunoreactivity, as identified here, may herald a significant reduction in survival.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0893-3952
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1555-62
pubmed:dateRevised
2007-12-3
pubmed:meshHeading
pubmed-meshheading:16998465-Antigens, CD4, pubmed-meshheading:16998465-Antigens, CD56, pubmed-meshheading:16998465-Antigens, Neoplasm, pubmed-meshheading:16998465-DNA Nucleotidylexotransferase, pubmed-meshheading:16998465-Dendritic Cells, pubmed-meshheading:16998465-Fluorescent Antibody Technique, Direct, pubmed-meshheading:16998465-Humans, pubmed-meshheading:16998465-Immunoenzyme Techniques, pubmed-meshheading:16998465-Killer Cells, Natural, pubmed-meshheading:16998465-Lectins, C-Type, pubmed-meshheading:16998465-Lymphoma, Non-Hodgkin, pubmed-meshheading:16998465-Membrane Glycoproteins, pubmed-meshheading:16998465-Plasma Cells, pubmed-meshheading:16998465-Receptors, Immunologic, pubmed-meshheading:16998465-Skin Neoplasms, pubmed-meshheading:16998465-Survival Rate, pubmed-meshheading:16998465-Tumor Markers, Biological
pubmed:year
2006
pubmed:articleTitle
Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms.
pubmed:affiliation
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. dljaye@emory.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural